1. Dynamin inhibition causes context-dependent cell death of leukemia and lymphoma cells.
- Author
-
von Beek C, Alriksson L, Palle J, Gustafson AM, Grujic M, Melo FR, Sellin ME, and Pejler G
- Subjects
- Animals, Apoptosis genetics, Bone Marrow Cells metabolism, Bone Marrow Cells pathology, Caspases blood, Caspases genetics, Cell Cycle genetics, Cell Line, Tumor, Child, Dynamins antagonists & inhibitors, Dynamins blood, Flow Cytometry, Heterografts, Humans, Mice, Pediatrics, Precursor Cell Lymphoblastic Leukemia-Lymphoma blood, Precursor Cell Lymphoblastic Leukemia-Lymphoma pathology, Cell Death genetics, Dynamins genetics, Endocytosis genetics, Precursor Cell Lymphoblastic Leukemia-Lymphoma genetics
- Abstract
Current chemotherapy for treatment of pediatric acute leukemia, although generally successful, is still a matter of concern due to treatment resistance, relapses and life-long side effects for a subset of patients. Inhibition of dynamin, a GTPase involved in clathrin-mediated endocytosis and regulation of the cell cycle, has been proposed as a potential anti-cancer regimen, but the effects of dynamin inhibition on leukemia cells has not been extensively addressed. Here we adopted single cell and whole-population analysis by flow cytometry and live imaging, to assess the effect of dynamin inhibition (Dynasore, Dyngo-4a, MitMAB) on pediatric acute leukemia cell lines (CCRF-CEM and THP-1), human bone marrow biopsies from patients diagnosed with acute lymphoblastic leukemia (ALL), as well as in a model of lymphoma (EL4)-induced tumor growth in mice. All inhibitors suppressed proliferation and induced pronounced caspase-dependent apoptotic cell death in CCRF-CEM and THP-1 cell lines. However, the inhibitors showed no effect on bone marrow biopsies, and did not prevent EL4-induced tumor formation in mice. We conclude that dynamin inhibition affects highly proliferating human leukemia cells. These findings form a basis for evaluation of the potential, and constraints, of employing dynamin inhibition in treatment strategies against leukemia and other malignancies., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2021
- Full Text
- View/download PDF